Specialty pharmacy s role in patient persistence compliance l.jpg
Sponsored Links
This presentation is the property of its rightful owner.
1 / 30

Specialty Pharmacy’s Role in Patient Persistence & Compliance PowerPoint PPT Presentation

  • Uploaded on
  • Presentation posted in: General

Specialty Pharmacy’s Role in Patient Persistence & Compliance. Dick Rylander President BioPharmaceutical Strategies LLC Former VP Commercial Operations & IT Actelion Pharmaceuticals, US. Speaking Qualifications. 26 years with Parke-Davis

Download Presentation

Specialty Pharmacy’s Role in Patient Persistence & Compliance

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript

Specialty pharmacy s role in patient persistence compliance l.jpg

Specialty Pharmacy’s Role in Patient Persistence & Compliance

Dick Rylander


BioPharmaceutical Strategies LLC

Former VP Commercial Operations & IT

Actelion Pharmaceuticals, US

Speaking qualifications l.jpg

Speaking Qualifications

  • 26 years with Parke-Davis

    • 16 product launches including Lopid; Lipitor; Rezulin; Procan SR; ERYC; Loestrin and others

    • Sales; management; marketing; managed care; incentive planning and special projects

  • 5 ½ years with Actelion Pharmaceuticals as VP Commercial Operations & IT

    • Developed the specialty distribution systems for Tracleer and Zavesca

      • Accredo; Caremark; PharmaCare; Gentiva and Curascript

    • Responsible for managed care; contracting; reimbursement services; IT; data/analytics; forecasting; inventory management, pricing, market research, training, sales force alignment, CRM…

Specialty vs retail l.jpg

Specialty vs. Retail

  • In the presentation we’ll:

    • Define the audiences

    • Outline some of their needs

    • Consider their different perspectives

    • Look at what impacts compliance

    • Share some examples of specialty efforts

    • Frame the strengths/weaknesses of various channels

    • Define when to use specialty

Who are the audiences l.jpg

Specialty Phcy





Retail Phcy

Who are the audiences?

Who is expecting what l.jpg


Who is expecting what?

  • They spend a LOT of money finding patients and getting an Rx written

  • 30-40% of Rx’s written never get filled

  • Dropout rates over the first 6-12 months are HIGH

  • Every patient retained as long as possible is one that contributes to sales and outcomes

Who is expecting what6 l.jpg


Who is expecting what?

  • They don’t now if they can afford the medication's)

  • They worry about side effects

  • They may not understand their disease

  • They may be afraid to ask questions

  • They may believe they need to make sacrifices to get and take their medications

Who is expecting what7 l.jpg

Retail Phcy

Who is expecting what?

  • Handle high volumes of patients

  • Are pressed to carve out time to counsel and advise patients

  • Work on small margins and are stretched thin

  • Have broad general knowledge of many diseases but may not have depth

  • Insurance is more focused on mass market high volume drugs where patients don’t need special support

Who is expecting what8 l.jpg

Specialty Phcy

Who is expecting what?

  • Mail Order rather than retail based (most)

  • Centralized personnel and services

  • Tend to deal heavily in smaller disease states

  • Tend to deal with more expensive medications

  • Deal with insurance plans for approval, appeals, etc., on a daily basis

  • May have more depth of knowledge in specialty diseases

Who is expecting what9 l.jpg


Who is expecting what?

  • They want to know that the medication is effective and will treat the condition…the first time

  • They need to believe that the treatment is cost effective

  • They need to know that this will reduce hospitalization, ER visits and other costly services

Who is expecting what10 l.jpg


Who is expecting what?

  • Needs to know their money is being well spent

  • That their long term cost exposure is limited

  • That the medication and treatment choices are right

  • That the therapeutic choices will reduce recurring costs

What are the common needs l.jpg

Specialty Phcy





Retail Phcy

What are the common needs?

  • Once an Rx gets to the pharmacy:

    • Get it filled quickly

    • At the lowest cost to the patient

    • Get refills fast

    • Answer questions

    • Minimize any concern that will stop the patient from taking the medication

    • Deal with any AE’s or SAE’s

    • If there are problems getting insurance approval or if the co-pay is too high get it resolved

    • Keep the patient on therapy for the duration of treatment

Compliance adherence and persistency l.jpg

Compliance, Adherence and Persistency

  • What are the barriers to patients getting and taking medications and continuing to get refills and what can Specialty Pharmacy do better than retail or manufacturers themselves?

Patient barriers l.jpg

Patient Barriers

  • Fear of medications

  • Fear of cost

  • Not understanding the disease

  • Worry about side effects

  • Insurance issues (poor or none)

  • Co-pay’s unaffordable

  • Misinformation

Access barriers l.jpg

Access Barriers

  • Formulary restrictions

  • Prior-Authorization process

  • Timing delays

  • Co-pay’s

Who are some of the major spp s l.jpg

Who are some of the major SPP’s?

  • Accredo (Medco)

  • Caremark

  • CuraScript/Priority (Express Scripts)

  • Aetna Specialty (Aetna)

  • PharmaCare (CVS)

  • RxCrossRoads (OmniCare)

  • Walgreens Specialty (Walgreens)

Statistics and data l.jpg

Statistics and Data

  • 75% of health plans use SPP’s

  • By 2008 biotech drugs may account for 25% of drug spend

  • There are over 600 biotech drugs in development which may require SPP’s

  • More and more drugs will be specialty and require special handling, education, training and assistance

Stats data l.jpg

Stats & Data

  • Clinical outcome programs administered by SPP’s:

    • MS: 95%+ compliance vs. 80% in retail

    • PAH: Flolan’s central line infection rate was .044 vs. a national average of .45 (a 10 fold difference)

    • Hemophilia: Option Care program after 3 years (in one case example) had a 96% compliance rate vs. <50% prior

    • RA: Caremark data shows 97% compliance vs. 78% at retail and adherence rates of 89% vs. 80%

Examples of programs at spp s l.jpg

Examples of programs at SPP’s


Examples of programs at spp s19 l.jpg

Examples of programs at SPP’s

Examples of programs at spp s20 l.jpg

Examples of programs at SPP’s

Accredo offered this example:

  • Unspecified Drug (confidentiality)

    • Known compliance issues (52-55%)

    • Built categories based on Pt. answers

    • Created risk identifiers

    • Model combined objective + subjective responses

  • Result: Compliance climbed to 90%

Oncologic value proposition l.jpg

ONCOLogic™ - Value Proposition

CuraScript has demonstrated superior Oncology patient management through compliance assistance programs:

  • Over 1,000 active patients on service for oral oncology agents

  • Xeloda Average Refill Rate 5.6 cycles/ Average Days 117.6

Compliance calculation report l.jpg

Compliance Calculation Report

  • CuraScripts approach to determining compliance results uses a formula:

Us bioservices l.jpg

US Bioservices

  • Harold G. Hilley, Vice President US Bioservices with 12 years in specialty suggests:

Actelion tracleer l.jpg

Actelion - Tracleer

When we planned for the launch we believed we would need certain services:

  • Each patient needed to be touched to understand their financial challenges, co-pay, etc.

  • Special effort made to get prior-auth approval

  • Someone to handle appeals of denials

  • Regular follow up with patients to make sure they got their questions answered

  • Access to payers, state Medicaid's, etc.

  • Monitoring and report of AE’s/SAE’s

Tracleer cont d l.jpg

Tracleer (cont’d)

  • We chose four (4) SPP’s based on their ability to meet our anticipated needs

  • We designed:

    • A closed data system with daily reporting

    • An incentive system to:

      • assure getting patients on therapy within defined periods of time

      • maintain patients on therapy

    • Reporting to tell us how they performed

Tracleer results l.jpg

Tracleer Results

  • We built an enrollment system that coordinated with the SPP’s to find those “in plan” with payers

  • We tracked the speed and identified reasons which cases were delayed and why

  • We worked with the SPP’s to understand why patients discontinued and built compliance efforts

  • We steadily improved the percentage of patients getting on and staying on therapy

How does specialty compare to retail l.jpg

How does Specialty compare to Retail?

When does it make sense to consider spp s l.jpg

When does it make sense to consider SPP’s?


  • Prescription volume is limited

  • It is a niche disease or smaller population

  • Patients are likely to have co-pay issues

  • Ongoing patient education & training is needed

  • Prior-Auth’s are likely

  • Side effects need to be managed

  • Appeals will be necessary

  • Quality data is needed

  • Quick response is important

  • You need better compliance, adherence and persistence

Spp s manufacturers l.jpg

SPP’s & Manufacturers

  • It’s a partnership

    • Sharing information

    • Consulting on outcome data and desired results

    • Developing marketing plans together

    • Planning for future success as a TEAM

References l.jpg


  • “The Rise and Role of Specialty Pharmacy” Biotechnology Healthcare October 2005. David Suchanek http://www.biotechnologyhealthcare.com/journal/fulltext/2/5/BH0205031.pdf

  • “A Practical Approach to Addressing a Longer-Term Benefits Strategy” Employee Benefit Plan review November 2005. David Carver and F. Randy Vogenberg http://www.aon.com/about/publications/pdf/issues/vogenberg_carver_practicalapproach_nov05.pdf

  • “Specialty Pharmacies Seek Ways to Deliver Financial and Clinical Outcomes to Payers” Specialty Pharmacy News July 2005. http://www.aishealth.com/DrugCosts/specialty/SPN_SPs_Seek_Ways_to_Deliver_Outcomes.html

  • “Overview of a Specialty Pharmacy” CuraScript Specialty Pharmacy Management Guide and Trend Report. 2004. http://www.express-scripts.com/ourcompany/news/industryreports/specialtytrendreport/2004/overview.pdf

  • DrugTrend Report: Managing Generation Rx. Vol 7, May 2005, Medco

  • Special case examples from Accredo; Caremark, CuraScript and US Bioservices

  • Login